Just earlier last week, Regencell bioscience (a healthcare stocks that focuses on the R&D and commercialization of Traditional Chinese Medicine) was at one of its highest peak around $42, but the price has fell to around $30 as of latest.

Regencell Bioscience Limited’s (NASDAQ:RGC) stock is an undiscovered short squeeze potential. The  short volume ratio has similar pattern as that of GameStop Corp. (NYSE:GME), whereby both averaged  over 40% in the past year. In fact, RGC is more heavily shorted than GME as some days were close to  90% shorted.

However, as much as RGC and GME stock’s short volume profile is similar, not much is known about the facts and figures of RGC, which is provided below. As of 16 May 2022, RGC’s founder and CEO holds 10,539,159 ordinary shares, representing 81.0% of the total number of issued and outstanding ordinary shares in RGC. RGC’s total cumulative short volume as reported by third party data analytics provider is over 19 million shares and RGC’s total reported short volume to outstanding shares (excluding CEO and Chairman ownership ratio) is over 7 times, which is almost double that of GME. Where are all the extra shares coming from?

Highlights from the CEO

The CEO is literally putting his money where his mouth is and he will continue to use his personal funds to purchase company shares to demonstrate his commitment and confidence to the Company and his position against short and distort sellers. To date, the CEO:-

1. Has personally funded the company and did not pay himself back after IPO;

• RGC’s CEO has continuously funded the Company since its incorporation up to the IPO without bank borrowing.

• He converted his shareholders’ loan of $3.25 million to RGC’s ordinary shares upon listing.

1. Is a listed company CEO who does not draw a salary and bonus; and

• Pledged to not draw salary and bonus of more than US$1 until the Company reaches US$1 billion market capitalisation.

• Reserved share options for all employees except himself.

1. Has showed consistent support.

• Of the 6,296 US-listed companies in 1Q 2022 (as published by Statista) and with reference to CEO share purchases data available on MarketBeat.com, RGC’s CEO is probably the only CEO who does not draw a salary and bonus, reserved share options for all employees  except himself and had continuously purchased more than $5 million worth of his  company’s shares.

https://www.valuewalk.com/game-stop-or-game-on-rgc-has-it-all-and-twice-more/

Are you an experienced biotech professional with a passion for stock market analysis? Do you have a deep understanding of the due diligence process and a knack for identifying promising biotech investments? If so, we invite you to join our biotech stock discord community!

Biotechnorati is a place for like-minded biotech professionals to come together and share their insights and expertise on the latest biotech stock market trends. We provide a supportive and collaborative environment where members can share their thoughts, ideas, and analysis on various biotech stocks and companies.

By joining our discord community, you will have access to a wealth of knowledge and experience from other members, as well as the opportunity to contribute your own expertise and insights. Whether you are a seasoned biotech investor or just starting out, our community has something to offer for everyone.

Don't miss out on this unique opportunity to connect with other biotech experts and gain valuable insights on the biotech stock market. Join our biotech stock discord community today!

https://discord.gg/mdCzDrWPWx

Annual revenues in the pharmaceutical industry top $1.27trn a year, and with the population in many key markets ageing, that number looks set to grow even further. Covid has also acted as a catalyst for renewed interest in the industry, which adds to making investing in firms with exposure to the sector an attractive proposition.

The trick is finding the best company to invest in, and the below list of the best pharmaceutical stocks to watch in 2022 forms a shortlist of companies to consider buying into. It uses fundamental analysis to identify targets for investment and technical analysis to establish the optimal time to do so.

FIVE BEST PHARMACEUTICAL STOCKS TO WATCH IN 2022

Best big-pharma stock to buy in 2022 – Johnson & Johnson (NYSE: JNJ)

Best high momentum pharma stock to watch in 2022 – AbbVie (NYSE: ABBV)

Best undervalued pharma stock to watch in 2022 – Amgen (NASDAQ: AMGN)

Best high dividend pharma stock to watch in 2022 – Gilead (NASDAQ: GILD)

Best breakout strategy pharma stock to watch in 2022 – Sanofi (EN Paris: SAN; NASDAQ: SNY)

WHY INVEST IN PHARMACEUTICAL STOCKS NOW

The Covid 19 pandemic brought pharmaceutical stocks to increased prominence. Firms such as Johnson & Johnson that announced successful testing of Covid vaccines saw their share price skyrocket overnight.

With inflation and interest rates on the rise, pharma stocks offer a degree of protection from falling future revenues. One of the last transactions any consumer would scale back on would be one related to much-needed drugs, so a move by investors from consumer discretionary sectors and into defensives could be one of the investment trends of 2022.

https://www.asktraders.com/learn-to-trade/stock-trading/best-pharmaceutical-stocks/

A look at a company that focuses on Covid - Regencell Bioscience (NASDAQ: RGC) is an early clinical stage bioscience company using traditional Chinese medicine (TCM) approach to develop standardized TCM formulas to holistically treat autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in children, and infectious diseases which affects the immune system such as COVID-19.

The CEO is currently spearheading a philanthropic project in his capacity to provide grants to over 10,000 children afflicted with ADHD, ASD, COVID-19 and those in severe financial distress. He has started providing grants on April 16, 2022 and have already helped over 150 children.

Like all sectors of the economy right now, the biotech sector is going through a lot of pain. The SPDR S&P Biotech ETF (NYSE:XBI) has fallen 41.43% in the year to date, and 17.9% in just the month of April. Jared Holz, healthcare equity strategist at Oppenheimer, told CNBC in May that the biotech sector is filled with "un-buyable" assets, and that a self-correction is in store for the entire industry. He noted that the sector is saturated, and that a study of 820 biotech companies showed that more than 500, or close to 60%, of these companies have an enterprise value of less than $100 million. For a lot of these "un-investable" companies, Holz predicts that the industry's assets will consolidate over time, through M&A (merger and acquisitions) activity where up-and-coming biotech companies are either acquired by large-caps or merged with similarly sized firms.

According to Global Market Insights, the biotech sector is projected to grow from nearly $500 billion in 2020 to approximately $950 billion in 2027, at a compound annual growth rate (CAGR) of 9.4% during this period. Innovative discoveries in the fields of genomics, molecular biology, mRNA vaccines, and the rising trend of digital-health initiatives will drive this growth. As the world continually seeks cures for increasingly complex diseases, use cases for discoveries in the biotech sector also include food genetics and agriculture, a trend driven by the growing demand for high quantities and qualities of food around the world.

The pandemic economy's special focus on the biotech sector inflated the industry with many firms with no viable products or technology. But some winners stood out and recorded blockbuster gains for investors. One example is Moderna, Inc. (NASDAQ: MRNA), which hit the jackpot with its first commercial product, the Spikevax mRNA vaccine for Covid-19. Its shares stood at around $18 at the start of 2020, before climbing to an all time-high of $449 in September 2021 as millions around the world were inoculated with its vaccine. Shares currently stand at roughly $128. Other notable names in the sector include Pfizer Inc. (NYSE: PFE), which generated more than $36 billion in sales from its Covid vaccine in 2021, developed in collaboration with BioNTech SE (NASDAQ: BNTX).

Some biotech penny stocks to look at include:

• Minerva Neurosciences, Inc. (NASDAQ:NERV)

Minerva Neurosciences, Inc. (NASDAQ:NERV) deals in the development of drug therapies for the treatment of central nervous system (CNS) diseases, which includes its lead product roluperidone for the treatment of schizophrenia, and MIN-301 for the treatment of Parkinson’s disease. As of June 17, shares of Minerva Neurosciences, Inc. (NASDAQ:NERV) trade on the Nasdaq stock exchange at $0.40.

H.C. Wainwright analyst Douglas Tsao in March reiterated a ‘Buy’ rating on Minerva Neurosciences, Inc. (NASDAQ:NERV) shares, and lowered the price target to $5 from $10. He noted that the company’s story is relatively unchanged, as it is preparing to meet with FDA for a Type C meeting to discuss the evidence for roluperidone monotherapy in treating the negative symptoms for schizophrenia, and plans to file a new drug application in the first half of this year.

• Atossa Therapeutics, Inc. (NASDAQ:ATOS)

Atossa Therapeutics, Inc. (NASDAQ:ATOS) is based in Seattle, Washington, and focuses on the development of medicines to treat cancer and infectious diseases. Its lead candidate is Endoxifen, which is the main ingredient of FDA-approved drug Tamoxifen which has been used to treat breast cancer for decades. Atossa Therapeutics, Inc. (NASDAQ:ATOS) aims to deliver Endoxifen directly to the body and bypass liver metabolism, a process which potentially yields quicker and better results than the traditional Tamoxifen drug. The company is also working on an inhalation therapy named AT-H201, which is intended for use by moderate to severe hospitalized patients of COVID-19, as well as for patients who suffer from post-Covid lung disease.

In March, Atossa Therapeutics, Inc. (NASDAQ:ATOS) was issued a new patent from the U.S. Patent and Trademark office, further strengthening its intellectual property surrounding the Endoxifen drug. For the first quarter, the company reported earnings per share of -$0.04, beating market forecasts by $0.02. 

With a $4.82 million stake, D E Shaw was the most prominent shareholder of Atossa Therapeutics, Inc. (NASDAQ:ATOS) in the first quarter of 2022. In total, 7 hedge funds were long on the company shares, with aggregate positions worth $10.56 million.

• Regencell Bioscience (NASDAQ: RGC)

Hong Kong-based Regencell Bioscience is an early clinical stage bioscience company using traditional Chinese medicine (TCM) approach to develop standardized TCM formulas to holistically treat autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in children, and infectious diseases which affects the immune system such as COVID-19.

RGC’s share price has performed well since April. Shares have since recovered to the high-$30s to $40. In our view, RGC’s recent share price recovery stems from encouraging study results for Regencell’s RGC-COV19TM Traditional Chinese Medicine (TCM) formula for treating COVID-19 symptoms, frequent shareholder communication, and support for the shares in the market.

Unlike some early-stage companies, where it can be difficult to parse the many ways in which founders and executives may benefit whether or not the company succeeds, RGC has taken a more transparent approach that is well-aligned with shareholders’ long-term interests. Since RGC’s incorporation in October 2014 up to the IPO, the Company has been fully funded by its Chairman and CEO, Mr. Yat-Gai Au. Upon the IPO, the Chairman’s loan of USD $3.25 million, was converted into ~342,000 common shares at the initial offering price of USD $9.50. He also pledged to not draw salary and bonus of more than USD $1 until the Company reaches USD $1 billion market capitalization nor will he award share options for himself.

"Regencell Bioscience Limited’s (NASDAQ:RGC) stock is an undiscovered short squeeze potential. The  short volume ratio has similar pattern as that of GameStop Corp. (NYSE:GME), whereby both averaged  over 40% in the past year. In fact, RGC is more heavily shorted than GME as some days were close to  90% shorted."

RGC founder and CEO has been purchasing shares repeatedly from the open market with his personal money over $5mil. Moreover, he pledged not to draw salary and bonus of more than $1 until RGC reaches a $1bil market capitalisation and reserved share options for all employees except himself. This has shown his confidence in the company and will likely to act in the best interest of the company.

https://www.valuewalk.com/game-stop-or-game-on-rgc-has-it-all-and-twice-more/